Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758004 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study Of Pediatric Appropriate Formulation
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00758004 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 76 participants.
The verdict
NCT00758004, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.
Interventions
- DRUG Atorvastatin
- DRUG Atorvastatin pediatric appropriate formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758004
The ClinicalTrials.gov registry entry for NCT00758004 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atorvastatin is the first listed.
NCT00758004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00758004 about?
NCT00758004 is a clinical study titled "Bioequivalence Study Of Pediatric Appropriate Formulation". To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.
What is the current status of trial NCT00758004?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2008-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00758004?
The interventions under investigation include: Atorvastatin (DRUG), Atorvastatin pediatric appropriate formulation (DRUG).
Who is sponsoring clinical trial NCT00758004?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.